Xenon制药将于2026年3月9日公布Azetukalner治疗局灶性发作的3期X-Tole2研究顶线结果

美股速递
Mar 09

Xenon制药宣布,计划于2026年3月9日(星期一)公布其候选药物Azetukalner针对局灶性发作性癫痫的3期临床试验X-Tole2研究的顶线结果。此次结果发布备受业界关注,将为评估该药物疗效与安全性的关键数据提供重要参考。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10